HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
Standard
HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. / Rollman, E; Arnheim, L; Collier, B; Oberg, D; Hall, H; Klingstrom, J; Dillner, Joakim; Pastrana, DV; Buck, CB; Hinkula, J; Wahren, B; Schwartz, S.
I: Virology, Vol. 322, Nr. 1, 2004, s. 182-189.Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
Harvard
APA
CBE
MLA
Vancouver
Author
RIS
TY - JOUR
T1 - HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses
AU - Rollman, E
AU - Arnheim, L
AU - Collier, B
AU - Oberg, D
AU - Hall, H
AU - Klingstrom, J
AU - Dillner, Joakim
AU - Pastrana, DV
AU - Buck, CB
AU - Hinkula, J
AU - Wahren, B
AU - Schwartz, S
PY - 2004
Y1 - 2004
N2 - Introduction of point mutations in the 5' end of the human papillomavirus type 16 (HPV-16) L1 gene specifically inactivates negative regulatory RNA processing elements. DNA vaccination of C57B1/6 mice with the mutated L1 gene resulted in improved immunogenicity for both neutralizing antibodies as well as for broad cellular immune responses. Previous reports on the activation of L1 by codon optimization may be explained by inactivation of the regulatory RNA elements. The modified HPV-16 L1 DNA that induced anti-HPV-16 immunity may be seen as a complementary approach to protein subunit immunization against papillomavirus.
AB - Introduction of point mutations in the 5' end of the human papillomavirus type 16 (HPV-16) L1 gene specifically inactivates negative regulatory RNA processing elements. DNA vaccination of C57B1/6 mice with the mutated L1 gene resulted in improved immunogenicity for both neutralizing antibodies as well as for broad cellular immune responses. Previous reports on the activation of L1 by codon optimization may be explained by inactivation of the regulatory RNA elements. The modified HPV-16 L1 DNA that induced anti-HPV-16 immunity may be seen as a complementary approach to protein subunit immunization against papillomavirus.
KW - imiquimod
KW - rGM-CSF
KW - T lymphocytes
KW - neutralization
KW - tumor immunity
KW - DNA vaccination
KW - HPV-16
U2 - 10.1016/j.virol.2004.02.002
DO - 10.1016/j.virol.2004.02.002
M3 - Article
C2 - 15063127
VL - 322
SP - 182
EP - 189
JO - Virology
JF - Virology
SN - 1096-0341
IS - 1
ER -